Furthermore, targeted STAT3 blocking/TLR9 activation resulted in differentiation of AML blasts to APCs with an activated DC phenotype, increased the ratio of tumor-infiltrating CD8+ T cells to regulatory T cells, and promoted CD8+ T cell dependent regression of leukemia (70). This evidence concerns the gene CD8A and neoplasm.